GROUPS

BWT
(g)

RV
(g)

LV
(g)

LV
WT/BWT

MAP
(mmHg)

Tau
(ms)

HR
(bpm)

SYS
(mmHg)

LV EDP
(mmHg)

LV +dP/dt
(mmHg/s)

LV -dP/dt
(mmHg/s)

Dead Volume
(ml)

LV PDP (mmHg)
Sham
N = 8		 378±18 0.18±0.10 0.80±.04 0.2±0.1 119±3 13.9±1.5 275±15 136±3 7±1 8138±426 6769±468 0.19±0.02 186±7
LVD
N = 4		 360±13 0.22±0.03 0.80±.02 0.2±0.1 118±8 18.2±0.7 252±17 136±8 8±1 6789±467 5067±591 0.21±0.04 163±10
CHF
N = 10		 350±9 0.41±0.03* 0.78±0.03 0.2±0.1 99±3* 24.2±1.4* 243±8 110±3* 26±1* 4890±193* 3073±142* 0.29±0.03* 118±3*
Sham NHE-1 1.0 mg/kg
N = 6		 359±5 0.19±0.03 0.76±0.02 0.2±0.0 119±1 13.6±1.2 292±13 136±3 5±1 8337±430 7205±550 0.14±0.01 178±16
LVD NHE-1 1.0 mg/kg
N = 7		 361±9 0.20±0.02 0.80±0.03 0.2±0.0 116±2 20.2±1.5 266±7 132±3 10±2 6404±256 4664±316 0.20±0.01 154±9
CHF NHE-1 1.0 mg/kg
N = 9		 360±9 0.38±0.01 0.72±0.03 0.2±0.0 95±4 23.0±1.0 237±4 108±5 23±1 5014±184 3099±112 0.22±0.02 123±3
Sham NHE-1 3 mg/kg
N = 11		 372±7 0.23±0.12 0.82±0.10 0.2±0.0 119±3 13.8±0.6 275±9 129±4 5±1 7938±362 6745±288 0.15±0.02 197±6
LVD NHE-1 3.0 mg/kg
N = 7		 368±7 0.24±0.01 0.85±0.03 0.2±0.0 106±3 18.5±1.5 273±13 121±4 9±1 6248±285 4604±272 0.24±0.03 161±2
CHF NHE-1 3.0 mg/kg
N = 9		 345±8 0.36±0.03 0.80±0.05 0.2±0.0 100±4 24.1±0.9 246±9 104±10 23±2 5069±260 3288±204 0.27±0.01 119±7

Body weight (BWT); right ventricular weight (RV); left ventricular weight (LV); LV/body weight ratio (LV WT/BW); left ventricular dysfunction (LVD); mean arterial pressure (MAP); heart rate (HR); LV end-diastolic pressure (EDP); LV peak developed pressure (LV PDP) *P< 0.05 Sham versus Severe CHF
>Table 1: In Vivo Hemodynamic Measurements

Figure 1: Ejection fraction in CHF rats. Baseline (N=36), 6wk control (N=6), 6wk 0.3mg (N=9), 6wk 1mg (N=10), 6wk 3mg (N=13). Data are mean + SE. * denotes statistical significance between baseline and all other groups (P < 0.05). ** denotes statistical significance for intergroup comparison (P < 0.05).

Figure 2: LV diastolic diameter in CHF rats. Baseline (N=36), 6wk control (N=6), 6wk 0.3mg (N=9), 6wk 1mg (N=10), 6wk 3mg (N=13). Data are mean + SE. * denotes statistical significance between baseline and all other groups (P < 0.05). ** denotes statistical significance for intergroup comparison (P < 0.05).

Figure 3: LV systolic diameter in CHF rats. Baseline (N=36), 6wk control (N=6), 6wk 0.3mg (N=9), 6wk 1mg (N=10), 6wk 3mg (N=13). Data are mean + SE. * denotes statistical significance between baseline and all other groups (P < 0.05). ** denotes statistical significance for intergroup comparison (P < 0.05).

Figure 1: Ejection fraction in CHF rats. Baseline (N=36), 6wk control (N=6), 6wk 0.3mg (N=9), 6wk 1mg (N=10), 6wk 3mg (N=13). Data are mean + SE. * denotes statistical significance between baseline and all other groups (P < 0.05). ** denotes statistical significance for intergroup comparison (P < 0.05).

Figure 2: LV diastolic diameter in CHF rats. Baseline (N=36), 6wk control (N=6), 6wk 0.3mg (N=9), 6wk 1mg (N=10), 6wk 3mg (N=13). Data are mean + SE. * denotes statistical significance between baseline and all other groups (P < 0.05). ** denotes statistical significance for intergroup comparison (P < 0.05).

Figure 3: LV systolic diameter in CHF rats. Baseline (N=36), 6wk control (N=6), 6wk 0.3mg (N=9), 6wk 1mg (N=10), 6wk 3mg (N=13). Data are mean + SE. * denotes statistical significance between baseline and all other groups (P < 0.05). ** denotes statistical significance for intergroup comparison (P < 0.05).

Figure 4: Pressure-volume relationship in Sham (N=8), Sham+3mg (N=11), CHF (N=10), and CHF+3mg (N=9) rats. There are no significant differences between the curves but with treatment both the sham and appear to show a trend of shifting toward the pressure axis.